Lexington-Fayette, Kentucky 2021-09-21 07:06:22 –
Johnson & Johnson said in a Phase 3 study Tuesday that booster shots of the COVID-19 vaccine showed a 94% increase in defense against moderate viruses in the United States.
Worldwide, J & J stated that booster shots are 75% effective against moderate cases of the virus and booster shots are 100% effective in preventing severe cases of COVID-19.
The company also said that when the booster shot was delivered two months after the first shot, antibody levels were 4-6 times higher than observed after the single shot.
“Our single-shot vaccine produces a strong immune response and long-term immunological memory, and given the booster immunity of the Johnson & Johnson COVID-19 vaccine, the defense against COVID-19 is even stronger. “It will increase,” said Dr. Mathai Mammen, Global Head of Research and Development at Johnson & Johnson. Press release..
During the Phase 3 trial, authorities administered booster shots 56 days after the subject received the first vaccination. Johnson & Johnson is the only single-dose vaccine approved for use in the United States.
J & J is also the only COVID-19 vaccine approved for use without mRNA technology.
Key panel Recommended last week All Americans over the age of 65 or those at risk of severe infection with the Pfizer vaccine look for booster shots 8 months after the first dose. Authorities then considered approving booster shots from another mRNA vaccine, Moderna, suggesting that the White House is likely to recommend J & J boosters in the future.
J & J also said on Tuesday that actual data showed that the COVID-19 vaccine was 79% effective against COVID-19 infection and 81% effective in preventing hospitalization.
“There was no evidence of reduced efficacy during the study, including when the delta variant became dominant in the United States,” the company said in a press release.